Sartorius Stedim Biotech (SDMHF) Expected to Announce Quarterly Earnings on Thursday

Sartorius Stedim Biotech (OTCMKTS:SDMHF) will likely be issuing its resultson Thursday, April 23rd. Analysts expect the company to announce earnings of $1.23 per share and revenue of $755.0090 million for the quarter.

Sartorius Stedim Biotech Stock Performance

SDMHF stock opened at $212.86 on Thursday. Sartorius Stedim Biotech has a 12-month low of $178.30 and a 12-month high of $264.30. The company’s fifty day simple moving average is $202.18 and its 200 day simple moving average is $224.07.

Wall Street Analyst Weigh In

SDMHF has been the topic of several recent analyst reports. Barclays restated an “overweight” rating on shares of Sartorius Stedim Biotech in a report on Tuesday, January 6th. The Goldman Sachs Group lowered shares of Sartorius Stedim Biotech from a “buy” rating to a “neutral” rating in a report on Monday, January 12th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Sartorius Stedim Biotech presently has a consensus rating of “Hold”.

About Sartorius Stedim Biotech

Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.

Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.